Cubist Systematic Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$4.84M Sell
8,600
-4,500
-34% -$2.54M 0.02% 988
2025
Q2
$6.88M Sell
13,100
-200
-2% -$112K 0.03% 822
2025
Q1
$8.44M Sell
13,300
-4,000
-23% -$2.75M 0.05% 574
2024
Q4
$12.3M Buy
17,300
+12,900
+293% +$10.8M 0.08% 379
2024
Q3
$4.63M Buy
+4,400
New +$4.9M 0.03% 878
2024
Q2
Sell
-8,300
Closed -$7.99M 3837
2024
Q1
$7.99M Sell
8,300
-12,600
-60% -$12M 0.05% 665
2023
Q4
$18.4M Sell
20,900
-3,300
-14% -$2.72M 0.12% 190
2023
Q3
$19.9M Buy
24,200
+2,000
+9% +$1.57M 0.15% 125
2023
Q2
$16M Buy
22,200
+3,400
+18% +$2.62M 0.11% 199
2023
Q1
$15.4M Buy
18,800
+8,800
+88% +$6.64M 0.09% 241
2022
Q4
$7.21M Buy
10,000
+7,500
+300% +$5.53M 0.04% 715
2022
Q3
$1.72M Sell
2,500
-3,600
-59% -$2.27M 0.01% 2158
2022
Q2
$3.61M Buy
+6,100
New +$3.97M 0.02% 1294

Other funds holding REGN

Cubist Systematic Strategies's REGN Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q3 2025, selling an estimated $8.86M and leaving 79,264 shares worth $44.6M. The position accounts for 0.21% of the portfolio, ranked #90.

Cubist Systematic Strategies first reported a position in REGN in Q2 2014 and has held it in 41 quarters since. The position peaked at $49.8M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Cubist Systematic Strategies held 79,264 shares of Regeneron Pharmaceuticals worth $44.6M as of Q3 2025.
  • Cubist Systematic Strategies sold 15,678 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $8.86M.
  • Regeneron Pharmaceuticals made up 0.21% of Cubist Systematic Strategies's portfolio in Q3 2025, its #90 holding.
  • Cubist Systematic Strategies first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
  • Cubist Systematic Strategies's Regeneron Pharmaceuticals position peaked at $49.8M in Q2 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.